Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 3/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17381648 | 0.96 | CCNA2 (0.35) | CCNA2CDK2CCNA1ACVR1CYP11B1 | |
| SCHEMBL17381637 | 0.93 | NR1H4 (0.35) | CCNA2CDK2CCNA1ACVR1CYP11B1 | |
| SCHEMBL17382120 | 0.92 | ALPL (0.31) | CCNA2CDK2CCNA1 | |
| SCHEMBL17382066 | 0.92 | CCNA2 (0.35) | CCNA2CDK2CCNA1ACVR1CYP11B1 | |
| SCHEMBL19321678 | 0.90 | NR1H4 (0.35) | CCNA2CDK2CCNA1CYP11B1CYP11B2 | |
| SCHEMBL17381651 | 0.89 | CCNA2 (0.32) | CCNA2CDK2CCNA1MKNK1MKNK2 | |
| SCHEMBL17382238 | 0.88 | NR1H4 (0.34) | MKNK1MKNK2NR1H4 | |
| SCHEMBL17382071 | 0.88 | MKNK1 (0.32) | CCNA2CDK2CCNA1ACVR1CYP11B1 | |
| SCHEMBL30681668 | 0.88 | MKNK1 (0.32) | CCNA2CDK2CCNA1ACVR1CYP11B1 | |
| SCHEMBL19321663 | 0.87 | NR1H4 (0.34) | CCNA2CDK2CCNA1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | TOCOPHERX, INC. (US) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253605-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | CCNA2 4240/4885CDK2 637/4885CCNA1 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.